Nasdaq:US$20.17 (-0.79) | HKEX:HK$31.70 (-1.70) | AIM:£3.24 (-0.13)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
公告及新聞稿
演示文稿
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
12345678
9
101112131415
找到相關結果： 738
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-17

和黃醫藥聯合阿斯利康開發的沃利替尼二線治療MET擴增的EGFR突變肺癌患者展現出良好的臨床抗腫瘤活性
– 沃利替尼聯合泰瑞莎® 或易瑞沙® 的臨床研究數據於世界肺癌大會公佈–   –新公佈的數據有助於理解MET 擴增的EGFR突變NSCLC的疾病進展過程和探索潛在的新一代治療策略–   
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-16

和黃醫藥公佈呋喹替尼聯合療法用於肺癌一線治療的II期臨床研究初步結果
– 呋喹替尼聯合易瑞沙® （吉非替尼）展現出良好的療效和安全性–   – 進一步證實呋喹替尼因其高選擇性和出眾的安全性而具有與其他癌症療法相聯合的巨大潛力–   2017年10
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 集團 | 2017-10-12

和黃醫藥董事會董事任命
2017 年10 月12 日：和黃中國醫藥科技有限公司（簡稱“ 和黃醫藥 ”或“Chi-Med”）（納斯達克/倫敦證交所：HCM）今日宣布任命莫樹錦（Tony Mok ）教授擔任公司獨立非執行董事，同時擔任
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-09-29

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting
Press Release   – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-09-29

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting
Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly
閱讀更多
公告及新聞稿, 監管通知 | 2017-09-29

Total Voting Rights
London: Friday, September 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 29, 2017, the issued share capital of Chi-Med consisted of 60,750,132 ord
閱讀更多
公告及新聞稿, 監管通知 | 2017-08-31

Director's Share Dealing
London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To,
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-08-29

和黃醫藥在中國啟動高選擇性PI3Kδ抑製劑HMPL-689以淋巴瘤為適應症的I期臨床試驗
2017年8月29日：和黃醫藥今日宣佈在中國啟動HMPL-689的I期臨床試驗。HMPL-689是一種新型高選擇性強效小分子抑製劑，靶向B 細胞受體信號通路中的關鍵蛋白磷酸肌醇-3激酶δ異構體（PI3Kδ）。
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-08-22

Director's Share Dealing
London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of
閱讀更多
公告及新聞稿, 監管通知 | 2017-08-18

Directors' Share Dealing
London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely
閱讀更多
公告及新聞稿, 監管通知 | 2017-08-15

Directors' Share Dealing
London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (
閱讀更多
公告及新聞稿, 監管通知 | 2017-08-10

Director’s Share Dealing
London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th
閱讀更多
公告及新聞稿, 監管通知 | 2017-08-07

Directors' Share Dealing
London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P
閱讀更多
公告及新聞稿, 集團 | 2017-07-31

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs
London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob
閱讀更多
公告及新聞稿, 監管通知 | 2017-06-30

Total Voting Rights
London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shar
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-29

和黃醫藥與阿斯利康聯手啟動沃利替尼治療乳頭狀腎細胞癌的全球III期臨床試驗“SAVOIR”
阿斯利康製藥（“阿斯利康”） (LON/STO/NYSE: AZN) 和黃中國醫藥科技有限公司 （簡稱 “和黃醫藥”） （納斯達克/倫敦證交所：HCM）   2017 年6 月29 日：和黃醫藥今日宣布
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-06-29

Blocklisting Six Monthly Return
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2017-06-29

Chi-Med to Announce 2017 Half-Year Financial Results
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-22

和黃醫藥在中國啟動新型FGFR抑製劑HMPL 453的I/II期臨床試驗
2017年6月22日：和黃醫藥近日在中國啟動HMPL-453的I/II期臨床試驗。HMPL-453是一種靶向成纖維細胞生長因子受體（FGFR）的新型高選擇性小分子抑製劑。2017年6月19日首位受試者接受給藥治療。該
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-06-16

Director’s Share Dealing
London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-12

和黃醫藥向國家食品藥品監督管理局遞交呋喹替尼治療晚期結直腸癌的新藥上市申請
  – 國家食品藥品監督管理局已受理申請，並將由藥品審評中心作技術審核–  –將收到來自禮來共計3080萬人民幣的里程碑付款–   2017年6月12日：和黃醫藥今日宣布藥物呋喹替
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-05

和黃醫藥在ASCO年會上就呋喹替尼臨床III期研究數據進行口頭報告
2017年6月5日：和黃醫藥宣佈在今天於美國芝加哥舉行的美國臨床腫瘤學會（ASCO）年會上就其自主研發的高選擇性血管細胞內皮生長因子受體（VEGFR）抑製劑的關鍵III期臨床研究結果進行了口
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-05-18

和黃醫藥在ASCO 2017年會上公佈臨床數據
  –受ASCO組委會邀請口頭報告呋喹替尼治療結直腸癌的III 期臨床研究“ FRESCO”的研究結果–    –將在大會上展示呋喹替尼，沃利替尼和索凡替尼共5項研究摘要–    2017年5
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-04-28

Total Voting Rights
London: Friday, April 28, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary sh
閱讀更多
公告及新聞稿, 監管通知 | 2017-04-27

Results of Annual General Meeting
London: Thursday, April 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2017 were duly
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-04-07

和黃醫藥在2017年AACR年會上公佈呋喹替尼和索凡替尼的臨床前數據
2017 年4 月7 日：和黃醫藥在2017 年4 月1 日至5 日於美國華盛頓舉行的美國癌症研究協會(AACR) 年會上公佈了呋喹替尼和索凡替尼的臨床前數據。呋喹替尼和索凡替尼目前都在以多種癌症
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2017-03-31

Total Voting Rights
London: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary sh
閱讀更多
公告及新聞稿, 監管通知 | 2017-03-29

Vesting of awards under the Long Term Incentive Plan
公告及新聞稿, 監管通知 | 2017-03-28

Grant of Share Options under Share Option Scheme
London: Tuesday, March 28, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 27, 2017, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
閱讀更多
公告及新聞稿, 集團 | 2017-03-27

2016 Annual Report and Notice of Annual General Meeting
London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2017-03-24

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors
Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-03-21

Chi-Med to host R&D Briefings on March 29 & 30, 2017
Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o
閱讀更多
公告及新聞稿, 監管通知 | 2017-03-20

Directors’ Share Dealing
London: Monday, March 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2017-03-16

Grant of Awards under Long Term Incentive Plan
Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a
閱讀更多
公告及新聞稿, 集團 | 2017-03-13

Publication of Form 20-F for the Year Ended December 31, 2016
London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww
閱讀更多
公告及新聞稿, 集團 | 2017-03-13

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-03-10

和黃醫藥在歐洲神經內分泌腫瘤學會年會上公佈索凡替尼治療神經內分泌瘤Ib /II期臨床試驗結果
2017 年3 月10 日：和黃醫藥在2017 年3 月8 日至10 日於西班牙巴塞羅那舉行的第14 屆歐洲神經內分泌腫瘤學會年會（ENETS）上公佈了索凡替尼正在進行的治療晚期神經內分泌瘤的Ib /II 期
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 腫瘤學 / 免疫學 | 2017-03-03

和黃醫藥宣布呋喹替尼（HMPL-013）以局部晚期或轉移性結直腸癌為適應症的III期臨床試驗“FRESCO”取得成功
– 達到首要和次要終點– –安全性及療效達到預期– – 計劃於2017年中遞交中國新藥上市申請– –完整詳細的試驗結果將在2017年中通過腫瘤學術大會公佈–   2017年3月3日：和黃醫
閱讀更多
查看公告 (PDF)
公告及新聞稿, 新聞稿, 集團 | 2017-02-28

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee
Change of Directors London: Tuesday, February 28, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Graeme Allan Jack has been appointed as I
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-02-20

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
Press Release London: Monday, February 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carci
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-02-14

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia
London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-453 in Australia.  HMPL-453 is a novel, highly
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-02-14

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium
Press Release London: Tuesday, February 14, 2017:  Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in patients wi
閱讀更多
公告及新聞稿, 監管通知 | 2017-02-06

Chi-Med to Announce 2016 Final Results
London: Monday, February 6, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2016 on Monday, March 13, 2017 at 7:00 am Greenwich Mean Time (GMT). An analy
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2017-02-01

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors
Change of Directors London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2017-01-16

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors
Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-16

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-16

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China.  Sulfatinib
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-16

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-01-10

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo
閱讀更多
公告及新聞稿, 監管通知 | 2016-12-30

Total Voting Rights
London: Friday, December 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 30, 2016, the issued share capital of Chi-Med consisted of 60,705,823 ordin
閱讀更多
12345678
9
101112131415